The Effects of Ganglioside-Monosialic Acid in Taxane-induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial.
暂无分享,去创建一个
J. Unger | X. An | L. Cai | Ying Lin | Zhongyu Yuan | Le-hong Zhang | W. Shi | R. Peng | C. Xue | Yanxia Shi | Jibin Li | Yong-Xiang Gao | Jinxin Zhang | Jia-jia Huang | Fei Xu | Shusen Wang | Jonathan Arias-Fuenzalida | R. Hong | W. Xia | Yanhong Su | Xinyue Wang | Yong-yi Zhong | Heng Huang | Anqin Zhang | Y. Zhong | Jiajia Huang | H. Huang
[1] L. Minasian,et al. Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715) , 2018, Journal of the National Cancer Institute.
[2] T. Julian,et al. Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30 , 2018, Journal of the National Cancer Institute.
[3] G. Cavaletti,et al. PERIPHERAL NEUROPATHIES: Chemotherapy‐induced peripheral neurotoxicity: management informed by pharmacogenetics , 2017 .
[4] N. Lunet,et al. Chemotherapy-induced peripheral neuropathy after neoadjuvant or adjuvant treatment of breast cancer: a prospective cohort study , 2016, Supportive Care in Cancer.
[5] S. Scarpa,et al. Taxane induced neuropathy in patients affected by breast cancer: Literature review. , 2015, Critical reviews in oncology/hematology.
[6] M. Ewertz,et al. Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. , 2015, European journal of cancer.
[7] Dawn L Hershman,et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] T. Schwarz,et al. The paradox of paclitaxel neurotoxicity: Mechanisms and unanswered questions , 2014, Neuropharmacology.
[9] M. Koltzenburg,et al. Chemotherapy‐induced peripheral neurotoxicity: A critical analysis , 2013, CA: a cancer journal for clinicians.
[10] G. Hortobagyi,et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Speck,et al. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. , 2013, Journal of oncology practice.
[12] C. Shapiro,et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. , 2013, JAMA.
[13] S. Jiao,et al. Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors , 2013, World Journal of Surgical Oncology.
[14] P. Novotny,et al. Further data supporting that paclitaxel‐associated acute pain syndrome is associated with development of peripheral neuropathy , 2012, Cancer.
[15] K. Fouad,et al. Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice , 2012, Proceedings of the National Academy of Sciences.
[16] P. Novotny,et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Antai Wang,et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy , 2011, Breast Cancer Research and Treatment.
[18] G. Cavaletti,et al. Chemotherapy-induced peripheral neurotoxicity , 2010, Nature Reviews Neurology.
[19] J. Schneider,et al. GM1 ganglioside in Parkinson's disease: Results of a five year open study , 2010, Journal of the Neurological Sciences.
[20] A. Valachis,et al. Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis. , 2010, Cancer treatment reviews.
[21] Sudhakar Tummala,et al. NCCN task force report: management of neuropathy in cancer. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[22] P. Mantyh,et al. The Paclitaxel Acute Pain Syndrome: Sensitization of Nociceptors as the Putative Mechanism , 2007, Cancer journal.
[23] H. Mouridsen,et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] D. Cella,et al. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study , 2006, International Journal of Gynecologic Cancer.
[25] S. Swain,et al. Peripheral neuropathy induced by microtubule-stabilizing agents. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] T. Ohgami,et al. Orally active neurotrophin-enhancing agent protects against dysfunctions of the peripheral nerves in hyperglycemic animals. , 2006, Diabetes.
[27] B. Overmoyer,et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] D. Fishman,et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (Fact/GOG‐Ntx) questionnaire for patients receiving systemic chemotherapy , 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
[29] David Cella,et al. Measuring the side effects of taxane therapy in oncology , 2003, Cancer.
[30] J. Chang,et al. Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. , 2000, European journal of cancer.
[31] E. Mamounas,et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Y. Fang,et al. The Role of GM1 and Other Gangliosides in Neuronal Differentiation Overview and New Findings a , 1998, Annals of the New York Academy of Sciences.
[33] H. Gogas,et al. The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. , 1996, Gynecologic oncology.
[34] W. B. Derry,et al. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. , 1996, Cancer research.
[35] M. Hamaguchi,et al. Ganglioside GM1 binds to the Trk protein and regulates receptor function. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[36] D. Tulsky,et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] J. Schneider,et al. Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment. , 1992, Science.
[38] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[39] R. Brady,et al. Biosynthesis and function of gangliosides. , 1976, Science.
[40] S. Mabuchi,et al. Usefulness of duloxetine for Paclitaxel-induced peripheral neuropathy treatment in gynecological cancer patients. , 2015, Anticancer research.
[41] T. Huanmanop,et al. Ganglioside GM1 (porcine) ameliorates paclitaxel-induced neuropathy in rats. , 2009, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[42] J. Manfredi,et al. Taxol: an antimitotic agent with a new mechanism of action. , 1984, Pharmacology & therapeutics.